<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1052243361488264&amp;ev=PageView&amp;noscript=1">

Tissue Dissociation Steps Video


FlowMetric Fast Facts

  • Loyal Clients ranging from large pharma, biotech, to the hospital setting
  • Ability to measure up to 20 parameters simultaneously
  • Expertise in multiple species & sample types
  • Multi-City site experience, domestic & international
  • Philadelphia Business Journal award for "Best CRO" in 2012

Why Choose FlowMetric

FlowMetric was established to deliver decision-enabling data on programs that matter the most to you. Partners choose us because of our expertize, our focus, our approach and results we have delivered.

Learn More

A Video From FlowMetric's CEO & Founder


Get Our Latest Whitepaper

Computational Cytometry | Flow Cytometry Data Analysis in the Era of Quantitative Data Science

News from FlowMetric

  • Why Outsource Flow Cytometry? View Post Summary

    Make Your Decision With These 5 Questions

    You have just gotten approval to start a big phase 1 clinical trial and 172 precious blood samples are about to come through your door in about two months. What do you do? Do you clone yourself and your outstanding flow cytometry skills? Do you consider skipping sleep for a few weeks? Do you panic? Perhaps, you should consider outsourcing your flow cytometry analysis ...

    Read the full article »
  • Where did my cells go? On summer vacation??? View Post Summary

    Have you ever started a flow cytometry run and you cannot see any cells? This can be an alarming feeling, but some straightforward troubleshooting can usually help you find your missing cells. Check out these three questions to tackle common issues associated with disappearing cells.

    Read the full article »
  • Detecting Minimal Residual Disease by Flow Cytometry View Post Summary

    Unlike solid tumors, blood cancers such as acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) may be monitored by measuring the presence and frequency of cancerous blood cells in the peripheral blood or bone marrow. Minimal residual disease (MRD) assessment uses different techniques to measure the presence of malignant cells, even at low frequency, and has been used as a key prognostic for guiding treatment decisions in pediatric and adult leukemia patients and assigning patients into different MRD-based risk groups. [1]

    Read the full article »